Consensus Nurix Therapeutics, Inc.

Stocks

NRIX

US67080M1036

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-29 EDT			5-day change	1st Jan Change
27.12 ^USD	-0.51%		+6.31%	+42.96%

10-14	Nurix Therapeutics Insider Sold Shares Worth $528,528, According to a Recent SEC Filing	MT
10-13	Nurix Therapeutics' Enterprise Value Remains Underappreciated, RBC Capital Markets Says	MT

Evolution of the Average Target: Nurix Therapeutics, Inc.

Evolution of the Target Price: Nurix Therapeutics, Inc.

Changes in Analyst Recommendations: Nurix Therapeutics, Inc.

ead107bd.h9__EyGnOyaUUvotOd5DD_t1ii8zvNtbgWj3-PXf1ow.4ZjKIWrjShbuIqxsFK8wZqMhyGp58Ixj7QWcnoKX4_X275R1U59CVNw-nQ~f7e5271a1e7be6dbcb3bd7fc554cde9e

Analysts' recommendations: Nurix Therapeutics, Inc.

10-13	Nurix Therapeutics' Enterprise Value Remains Underappreciated, RBC Capital Markets Says	MT
10-13	Oppenheimer Adjusts Price Target on Nurix Therapeutics to $32 From $28, Maintains Outperform Rating	MT
10-13	RBC Trims Price Target on Nurix Therapeutics to $35 From $36, Keeps Outperform, Speculative Risk	MT
08-10	Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says	MT
08-10	RBC Adjusts PT on Nurix Therapeutics to $36 From $33, Maintains Outperform Speculative Risk Rating	MT
07-22	UBS Lifts Nurix Therapeutics Price Target to $31 From $23, Maintains Buy Rating	MT
07-13	Mizuho Raises Price Target on Nurix Therapeutics to $34 From $30, Keeps Outperform Rating	MT
07-10	Nurix Therapeutics' Roche Deal Seen Driving Long-Term Upside, RBC Capital Markets Says	MT
07-10	RBC Capital Raises Nurix Therapeutics Price Target to $33 From $30, Maintains Outperform Speculative Risk Rating	MT
06-08	Wells Fargo Downgrades Nurix Therapeutics to Equal Weight From Overweight, Adjusts Price Target to $25 From $28	MT
01-29	RBC Raises Price Target on Nurix Therapeutics to $30 From $28, Keeps Outperform, Speculative Risk	MT
01-20	RBC Trims Price Target on Nurix Therapeutics to $28 From $29, Keeps Outperform, Speculative Risk	MT
01-08	Morgan Stanley Upgrades Nurix Therapeutics to Overweight From Equal Weight, Raises Price Target to $36 From $15	MT
12-10	Mizuho Adjusts Price Target on Nurix Therapeutics to $30 From $24, Maintains Outperform Rating	MT
25-10-23	RBC Raises Price Target on Nurix Therapeutics to $29 From $28, Keeps Outperform, Speculative Risk	MT
25-10-22	Nurix Therapeutics, Inc. Initiates Daybreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia	CI
25-10-21	Mizuho Initiates Nurix Therapeutics at Outperform With $24 Price Target	MT
25-10-09	Nurix Therapeutics reports third quarter 2025 financial results and provides a corporate update	RE
25-07-10	Oppenheimer Adjusts Price Target on Nurix Therapeutics to $30 From $32, Maintains Outperform Rating	MT
25-07-10	UBS Adjusts Price Target on Nurix Therapeutics to $26 From $30, Keeps Buy Rating	MT
25-06-13	RBC Raises Price Target on Nurix Therapeutics to $28 From $27, Keeps Outperform, Speculative Risk	MT
25-04-10	UBS Adjusts Price Target on Nurix Therapeutics to $30 From $35, Keeps Buy Rating	MT
25-01-29	RBC Raises Price Target on Nurix Therapeutics to $27 From $26, Keeps Outperform, Speculative Risk	MT
24-12-06	BMO Capital Initiates Nurix Therapeutics at Outperform With $35 Price Target	MT
24-10-24	UBS Initiates Nurix Therapeutics With Buy Rating, $35 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	NURIX THERAPEUTICS, INC.					+26.56%
	WUXI APPTEC CO., LTD.					+41.72%
	ARGENX SE					+26.36%
	LONZA GROUP AG					+10.61%
	IQVIA HOLDINGS INC.					+10.61%
	BEONE MEDICINES AG					+16.9%
	REVOLUTION MEDICINES, INC.					+37.16%
	CELLTRION, INC.					+42.61%
	GENMAB A/S					-17.48%
	WUXI BIOLOGICS (CAYMAN) INC.					+30.19%
	Average					+22.52%
	Weighted average by Cap.					+22.74%